1
|
Watson N. General internal medicine: a neurology registrar's guide to making the most of medical attachments. Pract Neurol 2024; 24:440-441. [PMID: 38902014 DOI: 10.1136/pn-2024-004204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/09/2024] [Indexed: 06/22/2024]
Affiliation(s)
- Neil Watson
- Department of Clinical Neuroscience, Royal Infirmary of Edinburgh, Edinburgh, UK
| |
Collapse
|
2
|
Liu HC, Chiu MJ, Lin CH, Yang SY. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dement Geriatr Cogn Dis Extra 2020; 10:46-55. [PMID: 32308667 PMCID: PMC7154287 DOI: 10.1159/000506278] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Accepted: 01/29/2020] [Indexed: 12/31/2022] Open
Abstract
Introduction Blood biomarkers of Alzheimer's disease (AD) have attracted much attention of researchers in recent years. In clinical studies, repeated freeze/thaw cycles often occur and may influence the stability of biomarkers. This study aims to investigate the stability of amyloid-β 1–40 (Aβ<sub>1–40</sub>), amyloid-β 1–42 (Aβ<sub>1–42</sub>), and total tau protein (T-tau) in plasma over freeze/thaw cycles. Methods Plasma samples from healthy controls (n = 2), AD patients (AD, n =3) and Parkinson's disease patients (PD, n = 3) were collected by standardized procedure and immediately frozen at −80°C. Samples underwent 5 freeze/thaw (−80°C/room temperature) cycles. The concentrations of Aβ<sub>1–40</sub>, Aβ<sub>1–42</sub>, and T-tau were monitored during the freeze/thaw tests using an immunomagnetic reduction (IMR) assay. The relative percentage of concentrations after every freeze/thaw cycle was calculated for each biomarker. Results A tendency of decrease in the averaged relative percentages over samples through the freeze and thaw cycles for Aβ<sub>1–40</sub> (100 to 97.11%), Aβ<sub>1–42</sub> (100 to 94.99%), and T-tau (100 to 95.65%) was found. However, the decreases were less than 6%. For all three biomarkers, no statistical significance was found between the levels of fresh plasma and those of the plasma experiencing 5 freeze/thaw cycles (p > 0.1). Conclusions Plasma Aβ<sub>1–40</sub>, Aβ<sub>1–42</sub>, and T-tau are stable through 5 freeze/thaw cycles measured with IMR.
Collapse
Affiliation(s)
| | - Ming-Jang Chiu
- Neurology, National Taiwan University Hospital, Taipei, Taiwan.,Neurology, College of Medicine, National Taiwan University, Taipei, Taiwan.,Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, Taiwan
| | - Chin-Hsien Lin
- Neurology, National Taiwan University Hospital, Taipei, Taiwan
| | - Shieh-Yueh Yang
- MagQu Co., Ltd., New Taipei City, Taiwan.,MagQu LLC, Surprise, Arizona, USA
| |
Collapse
|
3
|
Tsvetkova DZ, Bergquist SH, Parker MW, Jarrett TL, Howell JC, Watts KD, Kollhoff A, Roberts DL, Hu WT. Fear and Uncertainty Do Not Influence Reported Willingness to Undergo Lumbar Punctures in a U.S. Multi-Cultural Cohort. Front Aging Neurosci 2017; 9:22. [PMID: 28239349 PMCID: PMC5300987 DOI: 10.3389/fnagi.2017.00022] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 01/27/2017] [Indexed: 12/03/2022] Open
Abstract
Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease and related disorders can provide early and accurate prediction of underlying neuropathology even when the clinical symptoms are mild, but lumbar punctures (LP) to obtain CSF can be perceived as frightening and invasive. We previously demonstrated that this negative perception of the LP is strongly associated with a negative LP experience in terms of discomfort and complications, but it is not known what factors can lead to a negative perception of the LP. It has also been proposed that LP is less well-perceived by adults in the U.S. compared to Europe and elsewhere, although there is a paucity of primary data to support this. To address these knowledge gaps, we conducted a survey of 237 younger and older adults in the Atlanta area including a significant number born outside of the U.S. (n = 82, 34%) to determine demographic, medical, and experiential factors associated with the perception of LP as well as the willingness to undergo LP for medical or research purposes. Our results show that one in four respondents in this cohort with limited first-hand LP experience viewed the LP as a frightening invasive procedure, but the majority (89%) were willing to undergo LP for medical reasons. General awareness of the LP was associated with both standard and negative views of the LP, but perception did not influence willingness to undergo the procedure. Multi-variate models showed that higher annual household income, not place of birth or past experience, was associated with greater willingness to undergo LPs. We conclude that Americans (born in the U.S. or abroad) are not resistant to LPs if there is useful information to improve their health, although there is limited enthusiasm to undergo LPs solely for research purposes. At the same time, we failed to find modifiable factors to improve the perception of LP among those who already perceive it as frightening and invasive. Future recruitment effort should target adults with no preconceived notion of the LP with emphasis on data related to safety and tolerability.
Collapse
Affiliation(s)
- Dobromira Z Tsvetkova
- Department of Neurology, Emory University School of Medicine, AtlantaGA, USA; Center for Neurodegenerative Diseases Research, Emory University School of Medicine, AtlantaGA, USA
| | - Sharon H Bergquist
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta GA, USA
| | - Monica W Parker
- Department of Neurology, Emory University School of Medicine, AtlantaGA, USA; Alzheimer's Disease Research Center, Emory University School of Medicine, AtlantaGA, USA
| | - Thomas L Jarrett
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta GA, USA
| | - Jennifer C Howell
- Department of Neurology, Emory University School of Medicine, AtlantaGA, USA; Center for Neurodegenerative Diseases Research, Emory University School of Medicine, AtlantaGA, USA; Alzheimer's Disease Research Center, Emory University School of Medicine, AtlantaGA, USA
| | - Kelly D Watts
- Department of Neurology, Emory University School of Medicine, AtlantaGA, USA; Center for Neurodegenerative Diseases Research, Emory University School of Medicine, AtlantaGA, USA; Alzheimer's Disease Research Center, Emory University School of Medicine, AtlantaGA, USA
| | - Alexander Kollhoff
- Department of Neurology, Emory University School of Medicine, AtlantaGA, USA; Center for Neurodegenerative Diseases Research, Emory University School of Medicine, AtlantaGA, USA; Alzheimer's Disease Research Center, Emory University School of Medicine, AtlantaGA, USA
| | - David L Roberts
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta GA, USA
| | - William T Hu
- Department of Neurology, Emory University School of Medicine, AtlantaGA, USA; Center for Neurodegenerative Diseases Research, Emory University School of Medicine, AtlantaGA, USA; Alzheimer's Disease Research Center, Emory University School of Medicine, AtlantaGA, USA
| |
Collapse
|